ARDX Stock Chart & Stats
$60.00
$0.00(0.00%)
At close: 4:00 PM EDT
$60.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$60.00 - $138.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$15.32B
Enterprise Value$1.24K
Total Cash (Recent Filing)$281.83M
Total Debt (Recent Filing)$256.19M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Oct 29, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding249,187,580
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$238.13Price Target Upside296.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$8.26B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And High Gross MarginsArdelyx has demonstrated substantial commercial scaling while maintaining very high gross margins. This combination indicates that product revenue can expand without proportionate cost of goods, supporting operating leverage and improving the company’s ability to fund growth as sales mature.
Strong Momentum Across Both Marketed ProductsDouble-digit growth from both commercial products provides broader support for Ardelyx’s revenue base than reliance on a single expanding indication. Higher dispenses, paid prescriptions, and physician adoption also suggest that commercial infrastructure is translating into ongoing product utilization.
Pipeline And Intellectual-property RunwayAdvancement of the ACCEL Phase III program expands the potential use of the tenapanor platform beyond current products. A broad patent estate with a potential runway through 2042 could support commercial durability and help preserve product economics if development and regulatory milestones are achieved.
Bears Say
The Company Remains Unprofitable And LeveragedArdelyx has not yet converted its growing product base into operating profitability, while debt materially exceeds equity. Until earnings improve, leverage can limit financial flexibility and increase the importance of successful cost control, revenue growth, and access to additional capital.
Persistent Negative Cash GenerationImproving cash burn is encouraging, but Ardelyx still consumes cash rather than generating it through operations. Continued negative free cash flow may require further debt or equity financing, potentially constraining investment choices and increasing dependence on a timely path to sustained profitability.
Payer Access Is Slowing IBSRELA AdoptionPayer utilization controls can lengthen the path from prescription to treatment and reduce the pace of new-patient additions. If these access requirements persist, they may weaken near-term IBSRELA growth, raise reimbursement-support costs, and make commercial execution less predictable.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $60.00 and its highest was $138.70 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $15.32B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Oct 29, 2026 which is in 29 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Aug 06, 2026. The company reported -$1.184 earnings per share for the quarter, missing the consensus estimate of -$1.099 by -$0.085.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.24.
How many shares outstanding does Ardelyx have?
Ardelyx has 249,187,580 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of -$1.184 in its last earnings report, missing expectations of -$1.099. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in MX:ARDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ardelyx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$238.13 (296.88% Upside)
$238.13 (296.88% Upside)
Blogger Sentiment
Bullish
MX:ARDX Sentiment 79%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $7.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
ARDX Company Deck
ARDX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly constructive commercial and financial picture — record quarterly revenue, double-digit year-over-year growth for both marketed products, improving losses and a pathway to profitability in 2027 — but is tempered by material payer-access headwinds that slowed new patient starts for IBSRELA, a lowered near-term guidance for IBSRELA, increased operating costs to address access challenges, and pulled longer-range XPHOZAH guidance pending regulatory/market clarity. Management has taken proactive remediation steps (IPN, enlarged FRM team, expanded sales force), retains confidence in long-term potential (including $1 billion IBSRELA ambition and tenapanor IP), and maintains solid liquidity, resulting in a net-positive but cautious outlook.View all MX:ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$238.13
▲(296.88% Upside)
Technical Analysis
Cormedix
―
Lexicon Pharmaceuticals
―
Enanta Pharmaceuticals
―
Diamedica Therapeutics
―
Phathom Pharmaceuticals
―